002437
vs
S
Shanghai Composite
002437
Over the past 12 months, Harbin Gloria Pharmaceuticals Co Ltd has outperformed Shanghai Composite, delivering a return of +37% compared to the Shanghai Composite's +22% growth.
Stocks Performance
002437 vs Shanghai Composite
Performance Gap
002437 vs Shanghai Composite
Performance By Year
002437 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Harbin Gloria Pharmaceuticals Co Ltd
Glance View
Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines. The company is headquartered in Beijing, Beijing and currently employs 4,769 full-time employees. The company went IPO on 2010-06-23. The firm's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The firm is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The firm distributes its products within domestic market and to overseas markets.
